CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. In addition to our fully-owned programs, we have established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases with high unmet need. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. We are headquartered in Basel, Switzerland with R&D operations in Cambridge, Massachusetts, USA and some business operations in London, United Kingdom.
CRISPR Therapeutics has raised capital from various sources to support the development of its CRISPR/Cas9 gene editing platform and programs. We have raised nearly $89 million in venture funding from leading venture capital firms Versant Ventures, SR One, New Enterprise Associates, Abingworth and Celgene Ventures. In addition to the venture funding, CRISPR Therapeutics has received funding from its corporate partners, Vertex Pharmaceuticals and Bayer AG, as well as institutional investors.
Strategic partnerships are a core component of our strategy to allow us to access capabilities and resources to support our therapeutic programs. CRISPR Therapeutics has currently established significant collaborations with industry-leading Biopharma companies in Vertex Pharmaceuticals and Bayer AG. Going forward, we are interested in partnering with biopharma companies, academic centers, universities and other relevant organizations to access technologies and other capabilities.